Envoya Emerges from Stealth Mode, Unveils Revolutionary Gene Therapy Drug Delivery Platform
Retrieved on:
Tuesday, December 12, 2023
Envoya, a Pioneering Company in the Biotechnology Sector, Today Announces the Soft Launch of its Revolutionary Drug Delivery Platform for Gene Therapy.
Key Points:
- Envoya, a Pioneering Company in the Biotechnology Sector, Today Announces the Soft Launch of its Revolutionary Drug Delivery Platform for Gene Therapy.
- Envoya's platform is a game-changer, designed to overcome the limitations of current gene therapy delivery technologies like viral vectors and lipid nanoparticles, which have been hindered by safety concerns, limited payload capacities and restricted tissue-targeting.
- "While investigating the gene therapy market, we realized the main limiting factors in the current drug delivery systems are limited payloads, toxicity and efficiency and targeting.
- Trinayan Kashyap remarks "Envoya's platform presents an optimized and precise delivery option for gene therapy, with the potential to revolutionize the therapeutic landscape of oncology and genetic disease".